Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for TGTX

Stock NameTG Therapeutics Inc
TickerTGTX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS88322Q1085
LEI529900X21UKABN9NJ529

Show aggregate TGTX holdings

News associated with TGTX

TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00 at B. Riley
TG Therapeutics (NASDAQ:TGTX – Get Free Report) had its price target lifted by investment analysts at B. Riley from $53.00 to $55.00 in a research note issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s target price points to a potential upside of 68.66% […] - 2025-09-19 03:07:07
Swiss National Bank Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Swiss National Bank decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,500 shares of the biopharmaceutical company’s stock after selling 2,800 shares during the quarter. Swiss National […] - 2025-08-15 05:37:05
Investors Purchase High Volume of Call Options on TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 8,800 call options on the company. Thisrepresentsanincreaseofapproximately53% compared to the typical volume of 5,744 call options. Insiders Place Their Bets In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the […] - 2025-08-06 04:24:50
TG Therapeutics (NASDAQ:TGTX) Shares Gap Down After Earnings Miss
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report)’s share price gapped down prior to trading on Monday following a dissappointing earnings announcement. The stock had previously closed at $35.02, but opened at $32.14. TG Therapeutics shares last traded at $29.24, with a volume of 2,088,694 shares. The biopharmaceutical company reported $0.17 earnings per share (EPS) […] - 2025-08-05 02:20:50
TG Therapeutics Becomes Oversold (TGTX)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-08-04 12:58:51
Kestra Private Wealth Services LLC Acquires Shares of 5,593 TG Therapeutics, Inc. (NASDAQ:TGTX)
Kestra Private Wealth Services LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 1st quarter, HoldingsChannel reports. The fund bought 5,593 shares of the biopharmaceutical company’s stock, valued at approximately $221,000. Several other hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. […] - 2025-07-29 04:40:50
Mutual of America Capital Management LLC Sells 782 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Mutual of America Capital Management LLC lowered its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 3.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 19,437 shares of the biopharmaceutical company’s stock after selling 782 shares during the quarter. Mutual of America Capital Management LLC’s […] - 2025-07-22 07:08:56
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Principal Financial Group Inc.
Principal Financial Group Inc. increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 841,011 shares of the biopharmaceutical company’s stock after purchasing an additional 10,827 shares during the […] - 2025-07-08 05:26:54
New York State Teachers Retirement System Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
New York State Teachers Retirement System grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 175.0% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 120,364 shares of the biopharmaceutical company’s stock after buying an additional 76,600 shares during the period. New York State Teachers Retirement System’s holdings in TG Therapeutics […] - 2025-07-07 05:03:28
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund
Illinois Municipal Retirement Fund decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 30.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 54,194 shares of the biopharmaceutical company’s stock after selling 23,907 shares during the period. Illinois Municipal […] - 2025-06-30 05:14:52
5,850 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Praxis Investment Management Inc.
Praxis Investment Management Inc. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,850 shares of the biopharmaceutical company’s stock, valued at approximately $231,000. Other large investors have also recently made […] - 2025-06-24 05:15:03
TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Trimmed by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. lowered its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 94.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,172 shares of the biopharmaceutical company’s stock after selling 96,908 shares during the period. […] - 2025-06-20 04:52:52
Analysts See 16% Upside For XSMO
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-13 08:21:41
GAMMA Investing LLC Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
GAMMA Investing LLC increased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 6,905.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 179,130 shares of the biopharmaceutical company’s stock after purchasing an additional 176,573 shares during the quarter. GAMMA Investing […] - 2025-06-09 05:02:58
Mackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Mackenzie Financial Corp lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 46.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,888 shares of the biopharmaceutical company’s stock after selling 7,609 shares during the […] - 2025-06-05 05:26:59
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 7.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 272,370 shares of the biopharmaceutical company’s stock after […] - 2025-06-01 05:37:02
Bank of America Corp DE Lowers Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Bank of America Corp DE cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 86.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 230,939 shares of the biopharmaceutical company’s stock after selling 1,466,433 shares during the quarter. […] - 2025-05-27 05:16:48
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 92,683 shares of the biopharmaceutical company’s stock after acquiring an additional 2,890 shares during the quarter. MIRAE […] - 2025-05-21 05:40:51
Balyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)
Balyasny Asset Management L.P. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,100 shares of the biopharmaceutical company’s stock, valued at approximately $274,000. Other institutional investors […] - 2025-05-18 05:45:17
TG Therapeutics Sees Unusually Large Options Volume (NASDAQ:TGTX)
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) was the recipient of some unusual options trading on Monday. Stock traders bought 8,465 call options on the stock. This represents an increase of approximately 46% compared to the average daily volume of 5,801 call options. TG Therapeutics Price Performance Shares of NASDAQ TGTX opened at $34.86 […] - 2025-05-07 02:20:52
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by NewEdge Advisors LLC
NewEdge Advisors LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 4,549.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,928 shares of the biopharmaceutical company’s stock after purchasing an additional 6,779 shares during the period. NewEdge […] - 2025-05-02 05:18:53
Envestnet Asset Management Inc. Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
Envestnet Asset Management Inc. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,111 shares of the biopharmaceutical company’s stock after purchasing an additional 5,135 shares during the period. Envestnet Asset Management Inc.’s […] - 2025-04-29 04:24:54
TG Therapeutics Reaches Analyst Target Price
In recent trading, shares of TG Therapeutics Inc (Symbol: TGTX) have crossed above the average analyst 12-month target price of $40.00, changing hands for $40.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on - 2025-04-25 08:00:38
481,989 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Raymond James Financial Inc.
Raymond James Financial Inc. purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 481,989 shares of the biopharmaceutical company’s stock, valued at approximately $14,508,000. Raymond James Financial Inc. owned about 0.31% […] - 2025-04-22 05:11:00
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Bank of Montreal Can
Bank of Montreal Can raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,016 shares of the biopharmaceutical company’s stock after acquiring an additional 1,357 shares […] - 2025-04-21 04:38:46
Legal & General Group Plc Sells 7,065 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Legal & General Group Plc reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.8% during the 4th quarter, HoldingsChannel reports. The fund owned 391,388 shares of the biopharmaceutical company’s stock after selling 7,065 shares during the quarter. Legal & General Group Plc’s holdings in TG Therapeutics were worth $11,781,000 as of […] - 2025-04-17 06:54:47
Norges Bank Makes New $12.09 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)
Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 401,495 shares of the biopharmaceutical company’s stock, valued at approximately $12,085,000. Norges Bank owned 0.26% of TG Therapeutics at the […] - 2025-04-08 05:26:51
Vanguard Group Inc. Grows Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
Vanguard Group Inc. increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,596,480 shares of the biopharmaceutical company’s stock after purchasing an additional 209,190 shares during the quarter. Vanguard Group Inc. owned […] - 2025-04-02 04:47:03
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 44.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 168,575 shares of the biopharmaceutical company’s stock after selling 136,762 shares during the period. Prudential Financial Inc.’s […] - 2025-04-01 06:04:49
KLP Kapitalforvaltning AS Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)
KLP Kapitalforvaltning AS bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,700 shares of the biopharmaceutical company’s stock, valued at approximately $924,000. Other large investors have also made changes to […] - 2025-04-01 05:11:08

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc TGTX holdings

DateNumber of TGTX Shares HeldBase Market Value of TGTX SharesLocal Market Value of TGTX SharesChange in TGTX Shares HeldChange in TGTX Base ValueCurrent Price per TGTX Share HeldPrevious Price per TGTX Share Held
2025-09-26 (Friday)16,059USD 570,095USD 570,095
2025-09-25 (Thursday)16,059USD 556,284TGTX holding decreased by -12365USD 556,2840USD -12,365 USD 34.64 USD 35.41
2025-09-24 (Wednesday)16,059USD 568,649USD 568,649
2025-09-17 (Wednesday)15,955USD 511,198TGTX holding increased by 798USD 511,1980USD 798 USD 32.04 USD 31.99
2025-09-16 (Tuesday)15,955USD 510,400USD 510,400
2025-09-12 (Friday)15,851USD 509,768USD 509,768
2025-09-11 (Thursday)15,851TGTX holding increased by 208USD 514,523TGTX holding increased by 8003USD 514,523208USD 8,003 USD 32.46 USD 32.38
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of TGTX by Blackrock for IE00B3VWM098

Show aggregate share trades of TGTX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY208 32.460* 34.81
2025-08-21SELL-64 28.770* 34.84 Profit of 2,230 on sale
2025-07-31BUY192 35.500* 34.88
2025-06-30SELL-128 35.990* 34.60 Profit of 4,429 on sale
2025-06-25SELL-64 37.260* 34.55 Profit of 2,211 on sale
2025-06-20SELL-128 36.020* 34.50 Profit of 4,416 on sale
2025-05-30BUY4,369 35.110* 34.20
2025-05-23BUY49 34.570* 34.16
2025-05-19SELL-49 34.980* 34.14 Profit of 1,673 on sale
2025-05-15SELL-147 33.590* 34.15 Profit of 5,020 on sale
2025-05-12SELL-49 34.990* 34.15 Profit of 1,674 on sale
2025-05-09SELL-49 33.640* 34.16 Profit of 1,674 on sale
2025-04-30SELL-49 45.510* 33.80 Profit of 1,656 on sale
2025-04-24SELL-98 40.300* 33.48 Profit of 3,281 on sale
2025-04-17SELL-49 38.320* 33.23 Profit of 1,628 on sale
2025-04-15SELL-147 39.030* 33.11 Profit of 4,867 on sale
2025-04-14SELL-147 38.410* 33.05 Profit of 4,858 on sale
2025-04-09SELL-196 35.850* 32.94 Profit of 6,457 on sale
2025-04-07SELL-343 37.250* 32.86 Profit of 11,272 on sale
2025-04-04SELL-490 37.350* 32.81 Profit of 16,077 on sale
2025-03-31BUY49 39.430* 32.58
2025-03-19SELL-98 42.470* 31.60 Profit of 3,097 on sale
2025-03-14SELL-294 40.840* 31.22 Profit of 9,178 on sale
2025-03-13SELL-98 37.060* 31.13 Profit of 3,051 on sale
2025-03-12SELL-1,666 37.230* 31.05 Profit of 51,724 on sale
2025-03-07SELL-98 38.440* 30.71 Profit of 3,010 on sale
2025-03-06SELL-147 35.190* 30.64 Profit of 4,505 on sale
2025-03-03SELL-49 34.420* 30.43 Profit of 1,491 on sale
2025-02-28SELL-294 30.090* 30.44 Profit of 8,948 on sale
2025-02-26SELL-49 29.340* 30.49 Profit of 1,494 on sale
2025-02-25SELL-147 29.210* 30.51 Profit of 4,485 on sale
2025-02-18BUY245 31.160* 30.50
2025-02-13BUY49 30.730* 30.49
2025-02-12BUY49 30.900* 30.48
2025-02-11BUY147 31.110* 30.46
2025-02-06BUY441 33.500* 30.30
2025-01-27BUY49 31.920* 29.79
2024-12-30BUY245 31.445* 29.68
2024-12-06BUY196 33.930* 29.36
2024-12-05BUY49 33.650* 29.21
2024-12-04BUY245 33.880* 29.05
2024-11-29BUY245 34.800* 28.40
2024-11-27BUY196 35.000* 27.83
2024-11-26BUY49 34.260* 27.54
2024-11-21BUY245 34.550* 26.40
2024-11-20BUY147 31.150* 26.13
2024-11-18BUY588 29.610* 25.66
2024-11-12BUY392 30.910* 25.31
2024-11-08BUY245 28.810* 25.05
2024-11-07BUY735 27.900* 24.84
2024-11-06BUY98 27.170* 24.64
2024-10-31BUY49 25.060* 24.19
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of TGTX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19223,436521528,99042.2%
2025-09-18285,336951689,51641.4%
2025-09-17385,4603,101964,47740.0%
2025-09-16278,85897711,84439.2%
2025-09-15301,3100780,88638.6%
2025-09-12336,457100978,21234.4%
2025-09-11297,67656701,89742.4%
2025-09-10357,886444859,88241.6%
2025-09-09296,4484,142737,44340.2%
2025-09-08397,277241978,82040.6%
2025-09-05313,94801,117,31228.1%
2025-09-04580,12015,985986,15858.8%
2025-09-03840,6441,5391,837,16045.8%
2025-09-02321,2845,786795,11940.4%
2025-08-29268,86290676,56439.7%
2025-08-28324,4030822,75639.4%
2025-08-27277,2334531,050,66026.4%
2025-08-26172,9101,200594,21429.1%
2025-08-25213,884495484,64944.1%
2025-08-22255,0555,823830,33330.7%
2025-08-21208,3591,109543,36338.3%
2025-08-20175,6790488,97035.9%
2025-08-19224,6990576,18239.0%
2025-08-18308,438857787,08839.2%
2025-08-15159,966862532,78830.0%
2025-08-14172,44820555,54031.0%
2025-08-13250,5101,750978,63425.6%
2025-08-12297,592603884,70333.6%
2025-08-11447,9428702,109,69821.2%
2025-08-08288,5043,0412,111,81513.7%
2025-08-07353,8601,3871,047,58033.8%
2025-08-06349,4261,4101,197,86829.2%
2025-08-05735,44562,3822,250,87732.7%
2025-08-041,755,476210,0395,190,35333.8%
2025-08-01368,8052,141987,17737.4%
2025-07-31150,574400639,44623.5%
2025-07-30210,780900859,84724.5%
2025-07-29182,630664595,88230.6%
2025-07-28191,9761,914719,77426.7%
2025-07-25211,597471630,22333.6%
2025-07-24232,071312721,59532.2%
2025-07-23213,6881,584567,36937.7%
2025-07-22157,6072,772516,45930.5%
2025-07-21159,5080474,73133.6%
2025-07-18284,552514710,27840.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.